Literature DB >> 34506825

Cancer and cardiovascular disease: The impact of cardiac rehabilitation and cardiorespiratory fitness on survival.

Tamara Williamson1, Chelsea Moran1, Daniele Chirico2, Ross Arena3, Cemal Ozemek4, Sandeep Aggarwal5, Tavis Campbell6, Deepika Laddu7.   

Abstract

BACKGROUND: Cancer survivors are at increased risk for cardiovascular disease (CVD)-related morbidity and mortality. Exercise-based cardiac rehabilitation (CR) programs improve CVD risk factors, including cardiorespiratory fitness (CRF). The purpose of this study was to investigate: (1) the association between CR completion and survival, and (2) whether CRF improvements translate to increased survival among patients with comorbid cancer and CVD.
METHODS: Patients with CVD and pre-existing cancer (any type) were referred to a 12-week exercise-based CR program between 01/1996 and 03/2016. Peak metabolic equivalents (METs) were assessed by graded exercise test pre-CR and at 12-weeks. Kaplan-Meier survival and multivariate cox regressions were performed to evaluate impact of CR completion and clinically-meaningful CRF improvements [ΔMETs≥1] on survival, adjusting for relevant covariates.
RESULTS: Among 442 patients with CVD and cancer referred to CR (67 ± 10 years; 22% women), 361 (82%) completed CR. 102 deaths were recorded during the 12-year observation period. Compared to patients who did not complete CR, patients with comorbid cancer who completed CR demonstrated a survival advantage (63% vs 80.1%, p < .001). CRF improved among completers during the 12-week program (mean change = 0.87 ± 0.93 METs, p < .001); 41% experienced a clinically-meaningful ΔMETs≥1. A survival advantage was not observed in completers who experienced a ΔMETs≥1 improvement (p = .254).
CONCLUSION: Completing a 12-week exercise-based CR program improved CRF and increased survival in patients with CVD and comorbid cancer. The results highlight the survival benefits of completing a CR program among CVD patients who experience added barriers imposed by cancer treatment and survival.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac rehabilitation; Cardio-oncology; Cardiorespiratory fitness; Cardiovascular disease; Exercise capacity; Survival; cancer

Mesh:

Year:  2021        PMID: 34506825      PMCID: PMC9178663          DOI: 10.1016/j.ijcard.2021.09.004

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.039


  28 in total

1.  Prognostic value of treadmill exercise testing in elderly persons.

Authors:  T Y Goraya; S J Jacobsen; P A Pellikka; T D Miller; A Khan; S A Weston; B J Gersh; V L Roger
Journal:  Ann Intern Med       Date:  2000-06-06       Impact factor: 25.391

2.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

3.  A population-based study of cardiovascular disease mortality risk in US cancer patients.

Authors:  Kathleen M Sturgeon; Lei Deng; Shirley M Bluethmann; Shouhao Zhou; Daniel M Trifiletti; Changchuan Jiang; Scott P Kelly; Nicholas G Zaorsky
Journal:  Eur Heart J       Date:  2019-12-21       Impact factor: 29.983

4.  Pan-Canadian development of cardiac rehabilitation and secondary prevention quality indicators.

Authors:  Sherry L Grace; Paul Poirier; Colleen M Norris; Garth H Oakes; Deborah S Somanader; Neville Suskin
Journal:  Can J Cardiol       Date:  2014-04-12       Impact factor: 5.223

5.  Exercise-based oncology rehabilitation: leveraging the cardiac rehabilitation model.

Authors:  Kim L Dittus; Susan G Lakoski; Patrick D Savage; Nathan Kokinda; Michael Toth; Diane Stevens; Kimberly Woods; Patricia OʼBrien; Philip A Ades
Journal:  J Cardiopulm Rehabil Prev       Date:  2015 Mar-Apr       Impact factor: 2.081

6.  Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. On behalf of the APPROACH investigators.

Authors:  W A Ghali; M L Knudtson
Journal:  Can J Cardiol       Date:  2000-10       Impact factor: 5.223

7.  Lifestyle Interventions to Improve Cardiorespiratory Fitness and Reduce Breast Cancer Recurrence.

Authors:  Mark J Haykowsky; Jessica M Scott; Kathryn Hudson; Neelima Denduluri
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

8.  Submaximal effort tolerance as a predictor of all-cause mortality in patients undergoing cardiac rehabilitation.

Authors:  Paul Feuerstadt; Andrew Chai; Paul Kligfield
Journal:  Clin Cardiol       Date:  2007-05       Impact factor: 2.882

9.  Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis.

Authors:  Satoru Kodama; Kazumi Saito; Shiro Tanaka; Miho Maki; Yoko Yachi; Mihoko Asumi; Ayumi Sugawara; Kumiko Totsuka; Hitoshi Shimano; Yasuo Ohashi; Nobuhiro Yamada; Hirohito Sone
Journal:  JAMA       Date:  2009-05-20       Impact factor: 56.272

10.  Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jessica M Scott; Emily C Zabor; Emily Schwitzer; Graeme J Koelwyn; Scott C Adams; Tormod S Nilsen; Chaya S Moskowitz; Konstantina Matsoukas; Neil M Iyengar; Chau T Dang; Lee W Jones
Journal:  J Clin Oncol       Date:  2018-06-12       Impact factor: 44.544

View more
  1 in total

1.  Effects of cardiac rehabilitation on elderly patients with Chronic heart failure: A meta-analysis and systematic review.

Authors:  Zhuang Chen; Ming Li; Chenghua Yin; Youbo Fang; Ye Zhu; Jing Feng
Journal:  PLoS One       Date:  2022-08-25       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.